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males, 10% and 7% were children and females respectively. Majority of the males
(79%) were between the ages of 15-35 years of age. On an average the direct cost
incurred to treat the injured cases (103) was PKR13,000 excluding subsidy of at least
PKR53,000. The total cost was PKR66,000 (USD805) and this cost shall be considered
as minimum cost. CONCLUSIONS: Motorcycle accidents are incurring huge eco-
nomic burden on society. Themorbidity andmortality can be reduced by legislative
action concerning helmet use, licensing and rigid enforcement of traffic laws. Re-
habilitation services for the victims to get fully recovered may also be provided to
reduce the future economic loss.
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OBJECTIVES: Orthopedic surgery has been associated with significant risk of de-
velop deep vein thrombosis (DVT). The objective of this study was to estimate the
cost-effectiveness of thromboprophylaxis therapies for prevention of DVT associ-
ated in patients undergoing hip surgery from an institutional perspective (Mexican
Social Security Institute, IMSS).METHODS: Economic and health consequences of
thromboprophylaxis were assessed through a six-state Markov model (one-year
time horizon, one-week cycles). Effectiveness measure was reduction in DVT (per
1000 patients). Effectiveness was estimated by local meta-analysis. Doses of alter-
natives compared were: warfarin (basecase, 5mg 30d); dalteparin (not listed in
Mexican formulary, 5000 IU/day 30d); acenocoumarol (4 mg/day 30d); enoxaparin
(40 mg/day 30d); nadroparin (5700 IU/day 30d) and unfractionated heparin (UFH)
plus warfarin (10000 IU/day 10dwarfarin 5 mg/day 20d). No prophylaxis was as-
sessed too. Resource use and unit costswere extracted from IMSS databases (dalte-
parin cost was provided by the manufacturer). Costs included outpatient and in-
patient services, medication costs, imaging and laboratory tests. Univariate
sensitivity analysis was performed. Acceptability curves were constructed.
RESULTS:DVT cases per alternativewere: warfarin 61 (CI 95% 60–62); dalteparin 33
(32–34); acenocoumarol 80 (78–82); enoxaparin 57 (56–58); nadroparin 67 (66–68);
no prophylaxis 212 (205–219) and UFH 229 (223–235). Per patient annual cost (2011
US$) were: warfarin $3071.34 ($3049.23- $3093.44); dalteparin $2,980.42 ($2958.14-
$3002.71); acenocoumarol $2966.93 ($2940.92–$2992.94); enoxaparin $3668.54
($3631.18–$3705.90); nadroparin $3291.15 ($3260.60–$3321.70); no prophylaxis
$3466.68 ($3407.63–$3525.73) and UFH $3356.00 ($3311.59–$3400.41). Warfarin was
dominated by dalteparin, Dalteparin is cost-saving, compared to enoxaparin, na-
droparin, UFH andno prophylaxis. Regardingwarfarin, ICER (per DVT case avoided)
of enoxaparin and acenocoumarol resulted in $149.30 ($146.24-$152.36) and $5.49
($5.38-5.61), respectively. Acceptability curves showed that results were robust.
CONCLUSIONS: At IMSS, dalteparin would be a cost-saving or cost-effective ther-
apy for thromboprophylaxis in patients undergoing hip surgery.
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OBJECTIVES: Cost-effectiveness of denosumab versus oral bisphosphonates in
PMO from a US third party payer perspective was evaluated.METHODS: A lifetime
cohort Markov model was developed with seven health states: well, hip fracture,
vertebral fracture, other osteoporotic fracture, post hip fracture, post vertebral
fracture, and dead. During each cycle, a patient could fracture, remain healthy,
remain in a post fracture state or die. Relative fracture risk reduction, background
fracture risks, mortality rates, utilities, medical and drug costs were derived using
published sources. Expected costs and quality-adjusted life years (QALYs) were
estimated for denosumab, risedronate, ibandronate, and generic alendronate in
the overall PMO population and high risk subgroups: 1) 2 of the 3 risks i.e.,
70years-old, bonemineral density T-score-3.0 and prevalent vertebral fracture,
and 2) 75 years-old. Costs and QALYs were discounted at 3% annually. Extensive
sensitivity analyseswere conducted.RESULTS: In the overall PMOpopulation, total
lifetime costs for alendronate, risedronate, denosumab, and ibandronate were
$55,500, $58,200, $58,800 and $59,800, respectively. Total QALYswere 8.33, 8.33, 8.37
and 8.32, respectively. The incremental cost-effectiveness ratio (ICER) for deno-
sumab versus generic alendronate was $103,000/QALY. Risedronate was domi-
nated by alendronate and ibandronate was dominated by denosumab. In high risk
subgroup (a), total costs for alendronate, denosumab, risedronate and ibandronate
were $60,900, $62,200, $64,100 and $66,600, respectively. Total QALYs were 7.27,
7.32, 7.27 and 7.26, respectively. Denosumab had an ICER of $28,200/QALY versus
generic alendronate and dominated all other strategies. Denosumab dominated all
strategies in women 75 years. Results between denosumab and generic alendro-
nate were most sensitive to the relative risk of hip fracture for denosumab and the
cost of denosumab. CONCLUSIONS: In each PMO population examined, deno-
sumab represented good value for money compared to branded bisphosphonates.
Furthermore, denosumab was either cost-effective or dominant compared to ge-
neric alendronate in the high-risk subgroups.
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OBJECTIVES: The study compares the cost-effectiveness of denosumab (Prolia®;
Amgen, Thousand Oaks, CA) to generic alendronate in preventing osteoporotic
fracture among elderlywomen in the US setting.METHODS:This study utilized the
published literature, government data and organization websites to obtain model
parameters and parameter ranges. It used a “backward induction model” to ana-
lyze incremental cost per quality adjusted life year (QALY) saved from a societal
perspective. The model evaluated women from age 50 to 95, using 5 year time
intervals for intermediate results. The willingness-to-pay cut-off threshold used
was $150,000/QALY. One-way sensitivity analyses and probabilistic sensitivity
analyses were conducted to examine the robustness of the findings. RESULTS:
When it was assumed that a patient could suffer at most one hip fracture, the
discounted cost of denosumab therapy was $15,797 more than alendronate ther-
apy, and the increased QALY was 0.007. This leads to an incremental cost-effec-
tiveness ratio (ICER) average estimate of $2,111,647. When a patient was assumed
to have at most two hip fractures and potentially experience other fractures after
the first hip fracture (e.g., fractures of the wrist, spine, etc.), denosumab therapy
would average 0.013 more QALYs than alendronate therapy, and the ICER was
estimated to be $1,176,275. One-way sensitivity analyses did not change the base
case results substantially. Probabilistic sensitivity analyses suggested that the
probabilities were very small of the ICER meeting conventional willingness-to-pay
cut-off ratios in both one-hip-fracture-model and two-or more-fractures-models.
CONCLUSIONS: In the base case, due to the high acquisition cost, denosumab was
not found to be cost-effective for the prevention of osteoporotic fractures com-
pared with generic alendronate. A large change in probability of hip fracture or
probabilities of all fractures could make it cost-effective, but this would likely re-
quire new predictive tools or biomarkers to target denosumab therapy to very
high-risk patients.
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OBJECTIVES: Juvenile Idiopathic Arthritis (JIA) is defined as arthritis (diagnosed by
limitation in mobility, pain, pressure and local heat) in 1 or more joints for more
than 6 weeks without an apparent etiology, prior to age 16 of age. In particular, the
presentation systemic JIA (sJIA) is manifested clinically as chronic arthritis accom-
panied by intermittent fever, rash, anemia, hepatomegaly and/or splenomegaly
and pericarditis and/or pleuritis, in both genders during all pediatric stages. To
evaluate the cost-effectiveness of different biological therapies and identify which
one is dominant for the treatment of sJIA in Mexico. METHODS: It was done an
evaluation of cost-effectiveness of using Tocilizumab, Etanercept, Adalimumab,
Infliximab and placebo as a treatment for sJIA in a model of decision time horizon
of 12 weeks. Costs are expressed in US dollars. RESULTS: Tocilizumab demon-
strated superior effectiveness in patients achieving 71.6% ACR Pedi 70, with a cost
per patient of $ 2,022, followed by Etanercept, Infliximab and Adalimumab with
24.8% at a cost of $ 1,260, $ 2,621 and $ 2,760 respectively in the base case. The
expected cost to achieve one patient reaching an ACR Pedi 70 was significantly
lower with tocilizumab than with the rest of the alternatives. The decision to use
Tocilizumab for the treatment of sJIA would reduce the cost of getting a patient to
achieve an ACR Pedi 70 in almost half the cost per response ratio calculated for
Etanercept and reducing this value by about three-quarters compared with the
estimated cost with Infliximab or Adalimumab. The results show that Tocilizumab
is cost-effective ($ 1,886) and the dominant alternative compared to Etanercept ($
2,702), Infliximab ($ 11,898) and Adalimumab ($ 12,835). CONCLUSIONS: The cost-
effectiveness analysis showed that tocilizumab is cost-effective and is the domi-
nant strategy over Infliximab, Adalimumab and Etanercept for the treatment of
sJIA in Mexico.
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OBJECTIVES: To determine the cost-effectiveness of treating Dupuytren’s contrac-
turewith collagenase clostridiumhistolyticum (CCH), limited fasciectomy (LF), and
percutaneous needle fasciotomy (PNF). METHODS: A Markov decision model was
constructed based on published reports of effectiveness, adverse consequences,
population-based preferences, andmedical costs for the treatment of Dupuytren’s
contracture – a debilitating condition of the hands. The study perspectivewas from
that of a US payer, such as a commercial insurer. The Markov model classified
patients as either experiencing 1) clinical success after treatment; 2) treatment
failure –resulting in the need for revision procedures; 3) disease progression; or 4)
death. The model used yearly cycles over a 30-year period and took into account
recurrence rates and common side effects with each treatment. Clinical trials eval-
uating the efficacy of the three approaches to treatment defined clinical success
inconsistently. As a consequence, the primary analysis assumed equal efficacy
across the treatments. Probabilistic sensitivity analysis was conducted using a
Monte Carlo simulationwith distributions for efficacy, adverse events, and costs. A
societal discount rate of 3% was used for both cost and effect. The results are
presented in terms of cost per quality-adjusted life years (QALYs). RESULTS: The
estimatedmean (SD) costs over the 30-year period for CCH, LF, and PNFwere $4,489
(418), $18,345 (294), and $14,970 (599), respectively. The number of QALYs for CCH
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